Company intelligence / Profile preview
Cenna Biosciences Inc.
La Jolla, California, United Statescennabiosciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cenna Biosciences is developing NubytideTM, a first-in-class, disease-modifying peptide drug for the prevention and treatment of Alzheimer's Disease. The company received a $2.7M Phase II SBIR grant from NIH/NIA in September 2024 to support early clinical development. Their approach focuses on inhibiting the production of Aβ, reducing markers of inflammation, and addressing Tau pathology.
- Therapeutic areas
- Neurology
- Modalities
- Peptide drugsSmall molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
National Institutes of Health
Beyond the preview
Go deeper on Cenna Biosciences Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cenna Biosciences Inc..